Neogen Announces First-Quarter 2025 Results
Neogen (NASDAQ: NEOG) announced its first-quarter results for fiscal year 2025, ending August 31, 2024. The company reported revenue of $217.0 million, a 5.3% decrease from the previous year. Neogen experienced a net loss of $12.6 million, or $(0.06) per diluted share, compared to a net income of $1.5 million in the prior year. Adjusted Net Income was $14.4 million, or $0.07 per diluted share, while Adjusted EBITDA reached $43.7 million.
The Food Safety segment saw a 4.2% decrease in revenue to $159.3 million, while the Animal Safety segment experienced an 8.1% decline to $57.6 million. Despite challenges, Neogen is maintaining its full-year guidance, expecting revenue between $925 million and $955 million, with Adjusted EBITDA ranging from $215 million to $235 million.
Neogen (NASDAQ: NEOG) ha annunciato i risultati del primo trimestre per l'anno fiscale 2025, conclusosi il 31 agosto 2024. L'azienda ha riportato entrate pari a 217,0 milioni di dollari, con un calo del 5,3% rispetto all'anno precedente. Neogen ha subito una perdita netta di 12,6 milioni di dollari, ovvero $(0,06) per azione diluita, rispetto a un reddito netto di 1,5 milioni di dollari nell'anno precedente. Il reddito netto rettificato è stato di 14,4 milioni di dollari, o $0,07 per azione diluita, mentre l'EBITDA rettificato ha raggiunto 43,7 milioni di dollari.
Il segmento Sicurezza Alimentare ha registrato una diminuzione del 4,2% delle entrate, scendendo a 159,3 milioni di dollari, mentre il segmento Sicurezza Animale ha subito un calo dell'8,1% arrivando a 57,6 milioni di dollari. Nonostante le sfide, Neogen sta mantenendo le sue previsioni per l'intero anno, prevedendo entrate tra 925 milioni e 955 milioni di dollari, con un EBITDA rettificato compreso tra 215 milioni e 235 milioni di dollari.
Neogen (NASDAQ: NEOG) anunció sus resultados del primer trimestre para el año fiscal 2025, que finalizó el 31 de agosto de 2024. La compañía reportó ingresos de 217,0 millones de dólares, una disminución del 5,3% con respecto al año anterior. Neogen experimentó una pérdida neta de 12,6 millones de dólares, es decir, $(0,06) por acción diluida, en comparación con una ganancia neta de 1,5 millones de dólares en el año anterior. El ingreso neto ajustado fue de 14,4 millones de dólares, o $0,07 por acción diluida, mientras que el EBITDA ajustado alcanzó 43,7 millones de dólares.
El segmento de Seguridad Alimentaria vio una disminución del 4,2% en los ingresos, cayendo a 159,3 millones de dólares, mientras que el segmento de Seguridad Animal experimentó una caída del 8,1% hasta 57,6 millones de dólares. A pesar de los desafíos, Neogen está manteniendo su orientación para todo el año, esperando ingresos entre 925 millones y 955 millones de dólares, con un EBITDA ajustado que oscila entre 215 millones y 235 millones de dólares.
Neogen (NASDAQ: NEOG)은 2025 회계 연도 첫 분기 결과를 발표했습니다. 이 회계 연도는 2024년 8월 31일에 끝납니다. 회사는 2억 1천7백만 달러의 수익을 보고했으며, 이는 지난해 같은 기간 대비 5.3% 감소한 수치입니다. Neogen은 1천260만 달러의 순손실을 기록했으며, 희석 주당 $(0.06) 손실을 보였습니다. 전년도에는 150만 달러의 순익을 기록했습니다. 조정된 순익은 1천440만 달러였고, 희석 주당 $0.07에 해당하며, 조정된 EBITDA는 4천370만 달러에 도달했습니다.
식품 안전 부문은 수익이 4.2% 감소하여 1억 5천930만 달러에 이르렀고, 동물 안전 부문은 8.1% 감소하여 5천760만 달러를 기록했습니다. 어려움 속에서도 Neogen은 연간 가이던스를 유지하고 있으며, 수익은 9억 2천5백만 달러에서 9억 5천5백만 달러 사이가 될 것으로 예상하고 있습니다. 조정된 EBITDA는 2억 1천5백만 달러에서 2억 3천5백만 달러 사이로 예상됩니다.
Neogen (NASDAQ: NEOG) a annoncé ses résultats du premier trimestre pour l'exercice 2025, se terminant le 31 août 2024. La société a déclaré un chiffre d'affaires de 217,0 millions de dollars, soit une diminution de 5,3 % par rapport à l'année précédente. Neogen a subi une perte nette de 12,6 millions de dollars, soit $(0,06) par action diluée, contre un résultat net de 1,5 million de dollars l'année précédente. Le résultat net ajusté s'est élevé à 14,4 millions de dollars, soit 0,07 $ par action diluée, tandis que l'EBITDA ajusté a atteint 43,7 millions de dollars.
Le segment Sécurité Alimentaire a connu une diminution de 4,2 % de ses revenus, atteignant 159,3 millions de dollars, tandis que le segment Sécurité Animale a enregistré une baisse de 8,1 % à 57,6 millions de dollars. Malgré ces défis, Neogen maintient ses prévisions pour l'ensemble de l'année, avec des revenus prévus entre 925 millions et 955 millions de dollars, et un EBITDA ajusté compris entre 215 millions et 235 millions de dollars.
Neogen (NASDAQ: NEOG) hat seine Ergebnisse für das erste Quartal des Geschäftsjahres 2025 bekannt gegeben, das am 31. August 2024 endete. Das Unternehmen berichtete von Einnahmen in Höhe von 217,0 Millionen Dollar, was einem Rückgang von 5,3% im Vergleich zum Vorjahr entspricht. Neogen verzeichnete einen Nettoverlust von 12,6 Millionen Dollar, oder $(0,06) pro verwässerter Aktie, im Vergleich zu einem Nettogewinn von 1,5 Millionen Dollar im Vorjahr. Das bereinigte Nettoergebnis betrug 14,4 Millionen Dollar, oder $0,07 pro verwässerter Aktie, während das bereinigte EBITDA 43,7 Millionen Dollar erreichte.
Der Bereich Lebensmittelsicherheit verzeichnete einen Rückgang der Einnahmen um 4,2% auf 159,3 Millionen Dollar, während der Bereich Tiersicherheit einen Rückgang um 8,1% auf 57,6 Millionen Dollar erlebte. Trotz der Herausforderungen hält Neogen an seiner Jahresprognose fest und erwartet Einnahmen zwischen 925 Millionen und 955 Millionen Dollar, mit einem bereinigten EBITDA von 215 Millionen bis 235 Millionen Dollar.
- Maintaining full-year guidance despite challenges
- Food Safety segment achieved 1.1% core growth
- Resolved system-related issues in distribution center
- Positive core revenue growth in Food Safety segment
- Adjusted EBITDA of $43.7 million, representing a 20.1% margin
- Revenue decreased by 5.3% to $217.0 million
- Net loss of $12.6 million, compared to net income in prior year
- Core revenue declined by 1.4%
- Gross margin decreased to 48.4% from 51.0% in the prior year
- Animal Safety segment experienced 7.8% core revenue decline
- Genomics business saw a mid-single-digit core revenue decline
Insights
Neogen's Q1 2025 results show mixed signals. The company reported a
Key points to consider:
- Core revenue decline of
1.4% , impacted by a3.9% negative currency effect - Gross margin decreased to
48.4% from51.0% last year - Food Safety segment showed
1.1% core growth, while Animal Safety declined7.8% - Maintained full-year guidance, suggesting confidence in recovery
The company's focus on gaining market share and resolving distribution issues is promising, but investors should monitor margin pressures and end-market conditions closely. The maintained outlook for FY2025 indicates potential for improvement in coming quarters.
Neogen's Q1 results reflect broader industry challenges and company-specific transitions. The
- Soft end-market conditions in Food Safety, yet positive core growth indicates market share gains
- Animal Safety segment near cyclical lows, with potential for recovery
- Increasing focus on food safety solutions amid recent high-profile contamination incidents
- Genomics business showing signs of stabilization with mid-single-digit decline
The company's strategic shift towards larger production animals in genomics and efforts to leverage its food safety expertise could drive future growth. However, the current market environment remains challenging, with currency headwinds and end-market softness persisting. Investors should monitor Neogen's ability to execute on margin improvement initiatives and capitalize on food safety concerns for potential upside.
- Revenue of
$217.0 million - Net loss of
$12.6 million $(0.06) - Adjusted Net Income of
$14.4 million $0.07 - Adjusted EBITDA of
$43.7 million - Maintaining full-year guidance.
"During the first quarter, the focus of our teams shifted from managing through the initial complexity of exiting the transition service agreements from the 3M transaction to gaining market share," said John Adent, Neogen's President and Chief Executive Officer. "The system-related issues in our distribution center that impacted our order fulfillment rates were resolved and the business was not constrained by shipping. In our Food Safety segment, we saw encouraging initial traction from our targeted share-gain activities and generated positive core revenue growth while continuing to navigate soft end-market conditions. In our Animal Safety segment, the end market is near what we believe are cyclical lows. However, sales of our products to end users remained supportive, with the decline in core revenue driven by a combination of mixed channel inventory movements at our distribution partners and timing impacts. Operationally, our margins in the quarter were affected by the lower total volumes, as well as some higher costs in the area of shipping and distribution. We have mitigating initiatives currently underway and will be taking additional targeted actions to protect margins."
Adent continued, "The value proposition of Neogen's food safety solutions and expertise has never been more relevant than it is today. We provide an important and relatively inexpensive line of defense in the rapid detection of contaminants in the production and distribution of food and beverages. As evidenced by some unfortunate higher-profile incidents recently, contaminated products reaching consumers is something we all work to avoid. Beyond the obvious tragic consequences that can result, the costs of any associated recalls, litigation, brand damage or even facility closures can be tremendous. In addition to our broad portfolio of globally validated products, we have longstanding experience as a trusted partner that we're able to leverage in structuring robust food safety testing programs to help avoid these outcomes. Our commercial teams are having an increasing amount of constructive dialogue with customers on this front and we're looking forward to continuing to demonstrate our capabilities as a reliable, knowledgeable source of leading food safety testing solutions."
Financial and Business Highlights
Revenues for the first quarter were
Net loss for the first quarter was
Gross margin was
First-quarter Adjusted EBITDA was
Food Safety Segment
Revenues for the Food Safety segment were
Animal Safety Segment
Revenues for the Animal Safety segment were
On a global basis, the Company's Genomics business experienced a core revenue decline in the mid-single-digit range, reflecting modest sequential improvement from the fourth quarter. Increased sales in international beef and dairy markets were offset by the impact of customer attrition in the
Liquidity and Capital Resources
As of August 31, 2024, the Company had total cash of
Fiscal Year 2025 Outlook
The Company is maintaining its full-year outlook. Revenue is expected to be in the range of
Conference Call and Webcast
Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company's financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen's website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing (800) 836-8184 (
About Neogen
Neogen is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen Corporation has developed comprehensive solutions spanning the Food Safety, Livestock and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the company's most recently filed Form 10-K.
NEOGEN CORPORATION | ||||||||
Three months ended August 31, | ||||||||
2024 | 2023 | |||||||
Revenue | ||||||||
Food Safety | $ | 159,345 | $ | 166,278 | ||||
Animal Safety | 57,619 | 62,709 | ||||||
Total revenue | 216,964 | 228,987 | ||||||
Cost of revenues | 112,038 | 112,226 | ||||||
Gross profit | 104,926 | 116,761 | ||||||
Operating expenses | ||||||||
Sales & marketing | 45,799 | 45,783 | ||||||
Administrative | 51,671 | 45,121 | ||||||
Research & development | 5,199 | 6,722 | ||||||
Total operating expenses | 102,669 | 97,626 | ||||||
Operating income | 2,257 | 19,135 | ||||||
Interest expense, net | (17,622) | (16,666) | ||||||
Other expense | (244) | (806) | ||||||
(Loss) income before tax | (15,609) | 1,663 | ||||||
Income tax (benefit) expense | (3,000) | 160 | ||||||
Net (loss) income | $ | (12,609) | $ | 1,503 | ||||
Net (loss) earnings per diluted share | $ | (0.06) | $ | 0.01 | ||||
Shares to calculate per share amount | 216,695,348 | 216,846,106 | ||||||
NEOGEN CORPORATION | ||||||||
August 31, 2024 | May 31, 2024 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 120,477 | $ | 170,611 | ||||
Marketable securities | — | 325 | ||||||
Accounts receivable, net of allowance of | 167,639 | 173,005 | ||||||
Inventories, net of reserves of | 198,596 | 189,267 | ||||||
Prepaid expenses and other current assets | 53,938 | 56,025 | ||||||
Total Current Assets | 540,650 | 589,233 | ||||||
Net Property and Equipment | 300,971 | 277,104 | ||||||
Other Assets | ||||||||
Right of use assets | 14,311 | 14,785 | ||||||
Goodwill | 2,137,494 | 2,135,632 | ||||||
Intangible assets, net | 1,489,751 | 1,511,653 | ||||||
Other non-current assets | 19,996 | 20,426 | ||||||
Total Assets | $ | 4,503,173 | $ | 4,548,833 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current Liabilities | ||||||||
Current portion of finance lease | $ | 2,651 | $ | 2,447 | ||||
Accounts payable | 61,464 | 83,061 | ||||||
Accrued compensation | 15,803 | 19,949 | ||||||
Income tax payable | 11,102 | 10,449 | ||||||
Accrued interest | 3,554 | 10,985 | ||||||
Deferred revenue | 5,635 | 4,632 | ||||||
Other accruals | 22,480 | 22,800 | ||||||
Total Current Liabilities | 122,689 | 154,323 | ||||||
Deferred Income Tax Liability | 317,574 | 326,718 | ||||||
Non-current debt | 889,129 | 888,391 | ||||||
Other non-current liabilities | 38,589 | 35,259 | ||||||
Total Liabilities | 1,367,981 | 1,404,691 | ||||||
Commitments and Contingencies | ||||||||
Equity | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 34,672 | 34,658 | ||||||
Additional paid-in capital | 2,588,930 | 2,583,885 | ||||||
Accumulated other comprehensive loss | (31,421) | (30,021) | ||||||
Retained earnings | 543,011 | 555,620 | ||||||
Total Stockholders' Equity | 3,135,192 | 3,144,142 | ||||||
Total Liabilities and Stockholders' Equity | $ | 4,503,173 | $ | 4,548,833 | ||||
NEOGEN CORPORATION | ||||||||
Three months ended August 31, | ||||||||
2024 | 2023 | |||||||
Cash Flows (used for) provided by Operating Activities | ||||||||
Net (loss) income | $ | (12,609) | $ | 1,503 | ||||
Adjustments to reconcile net (loss) income to net cash from operating activities: | ||||||||
Depreciation and amortization | 29,800 | 28,734 | ||||||
Deferred income taxes | (9,119) | 998 | ||||||
Share-based compensation | 3,982 | 2,638 | ||||||
Loss on disposal of property and equipment | 77 | — | ||||||
Amortization of debt issuance costs | 860 | 860 | ||||||
Other | (261) | — | ||||||
Change in operating assets and liabilities, net of business acquisitions: | ||||||||
Accounts receivable, net | 4,796 | 16,242 | ||||||
Inventories, net | (9,939) | (6,304) | ||||||
Prepaid expenses and other current assets | (1,733) | (12,925) | ||||||
Accounts payable and accrued liabilities | (15,881) | 4,980 | ||||||
Interest expense accrual | (7,431) | (7,711) | ||||||
Change in other non-current assets and non-current liabilities | (456) | (6,006) | ||||||
Net Cash (used for) provided by Operating Activities | (17,914) | 23,009 | ||||||
Cash Flows used for Investing Activities | ||||||||
Purchases of property, equipment and other non-current intangible assets | (38,433) | (30,630) | ||||||
Proceeds from the maturities of marketable securities | 325 | 21,905 | ||||||
Proceeds from the sale of property and equipment and other | 4,446 | 41 | ||||||
Net Cash used for Investing Activities | (33,662) | (8,684) | ||||||
Cash Flows provided by Financing Activities | ||||||||
Exercise of stock options and issuance of employee stock purchase plan shares | 1,077 | 1,062 | ||||||
Repayment of long-term debt and finance lease | (98) | — | ||||||
Net Cash provided by Financing Activities | 979 | 1,062 | ||||||
Effects of Foreign Exchange Rate on Cash | 463 | 205 | ||||||
Net (Decrease) Increase in Cash and Cash Equivalents | (50,134) | 15,592 | ||||||
Cash and Cash Equivalents, Beginning of Year | 170,611 | 163,240 | ||||||
Cash and Cash Equivalents, End of Year | $ | 120,477 | $ | 178,832 | ||||
Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.
Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.
Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the effects of foreign currency translation rates and the first-year impacts of acquisitions and discontinued product lines, where applicable. Core revenue growth is presented to allow for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency translation rates, or the incomparability that would be caused by the impact of an acquisition, disposal or product line discontinuation.
These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP.
NEOGEN CORPORATION | ||||||||
Three months ended August 31, | ||||||||
2024 | 2023 | |||||||
Net (loss) income | $ | (12,609) | $ | 1,503 | ||||
Income tax (benefit) expense | (3,000) | 160 | ||||||
Depreciation and amortization | 29,800 | 28,734 | ||||||
Interest expense, net | 17,622 | 16,666 | ||||||
EBITDA | $ | 31,813 | $ | 47,063 | ||||
Share-based compensation | 3,982 | 2,638 | ||||||
FX transaction gain on loan and other revaluation (1) | (320) | (290) | ||||||
Certain transaction fees and integration costs (2) | 5,122 | 1,951 | ||||||
Severance and other employment costs | 370 | 559 | ||||||
Contingent consideration adjustments | — | 300 | ||||||
ERP expense (3) | 1,835 | 128 | ||||||
Discontinued product line expense (4) | 912 | 20 | ||||||
Adjusted EBITDA | $ | 43,714 | $ | 52,369 | ||||
Adjusted EBITDA margin (% of sales) | 20.1 | % | 22.9 | % | ||||
(1) Net foreign currency transaction loss associated with the revaluation of foreign denominated intercompany loans |
(2) Includes costs associated with the 3M transaction, including various transition agreements. |
(3) Expenses related to ERP implementation. |
(4) Expenses associated with certain discontinued product lines. Amounts are recorded within Cost of Revenues. |
NEOGEN CORPORATION | ||||||||
Three months ended August 31, | ||||||||
2024 | 2023 | |||||||
Net (loss) income | $ | (12,609) | $ | 1,503 | ||||
Amortization of acquisition-related intangibles | 23,138 | 23,325 | ||||||
Share-based compensation | 3,982 | 2,638 | ||||||
FX transaction gain on loan and other revaluation (1) | (320) | (290) | ||||||
Certain transaction fees and integration costs (2) | 5,122 | 1,951 | ||||||
Severance and other employment costs | 370 | 559 | ||||||
Contingent consideration adjustments | — | 300 | ||||||
ERP expense (3) | 1,835 | 128 | ||||||
Discontinued product line expense (4) | 912 | 20 | ||||||
Estimated tax effect of above adjustments (5) | (8,052) | (6,447) | ||||||
Adjusted Net Income | $ | 14,378 | $ | 23,687 | ||||
Adjusted Earnings per Share | $ | 0.07 | $ | 0.11 | ||||
(1) Net foreign currency transaction loss associated with the revaluation of foreign denominated intercompany loans |
(2) Includes costs associated with the 3M transaction, including various transition agreements. |
(3) Expenses related to ERP implementation. |
(4) Expenses associated with certain discontinued product lines. Amounts are recorded within Cost of Revenues. |
(5) Tax effect of adjustments is calculated using projected effective tax rates for each applicable item. |
NEOGEN CORPORATION | ||||||||||||||||
Q1 FY25 | Q1 FY24 | Growth | Foreign Currency | Acquisitions / | Core Revenue | |||||||||||
Food Safety | $ | 159,345 | $ | 166,278 | (4.2 %) | (5.4 %) | 0.1 % | 1.1 % | ||||||||
Animal Safety | 57,619 | 62,709 | (8.1 %) | 0.0 % | (0.3 %) | (7.8 %) | ||||||||||
Total Neogen | $ | 216,964 | $ | 228,987 | (5.3 %) | (3.9 %) | 0.0 % | (1.4 %) | ||||||||
Contact
Bill Waelke
(517) 372-9200
ir@neogen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-first-quarter-2025-results-302272424.html
SOURCE Neogen Corporation
FAQ
What was Neogen's revenue for Q1 2025?
How did Neogen's NEOG stock perform in terms of earnings per share in Q1 2025?
What was Neogen's Adjusted EBITDA for Q1 2025?
How did Neogen's Food Safety segment perform in Q1 2025?
What is Neogen's revenue guidance for fiscal year 2025?
